SH
KPTI icon

Sandia Holdings’s Karyopharm Therapeutics KPTI Stock Holding History

Sandia Holdings’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$2.04M Hold
7,983
– – 0.96% 19
2018
Q2 		$2.03M Buy
+7,983
New +$1.97M 0.91% 20

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sandia Holdings's KPTI Position: Q3 2018 in Review

Sandia Holdings held its Karyopharm Therapeutics (KPTI) position steady in Q3 2018 at 7,983 shares worth $2.04M. The position accounts for 0.96% of the portfolio, ranked #19.

Sandia Holdings first reported a position in KPTI in Q2 2018 and has held it in 2 quarters since. 119 funds tracked by Wall St. Rank hold KPTI as of Q3 2018.

  • Sandia Holdings held 7,983 shares of Karyopharm Therapeutics worth $2.04M as of Q3 2018.
  • Sandia Holdings left its Karyopharm Therapeutics share count unchanged in Q3 2018.
  • Karyopharm Therapeutics made up 0.96% of Sandia Holdings's portfolio in Q3 2018, its #19 holding.
  • Sandia Holdings first reported a position in Karyopharm Therapeutics in Q2 2018 and has held it in 2 quarters since.
  • 119 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2018.

Based on Sandia Holdings's 13F filing for Q3 2018, filed 13 Nov 2018.